Menopause: The Journal of The North American Menopause Society最新文献

{"title":"Efficacy and safety of Matricaria chamomilla intervention in managing menopausal symptoms: a triple-blind clinical trial.","authors":"Farideh Mohsenzadeh-Ledari, Mouloud Agajani Delavar, Ali Akbar Moghadamnia, Soraya Khafri, Reza Bekhradi, Fereshteh Behmanesh, Shahla Yazdani","doi":"10.1097/GME.0000000000002496","DOIUrl":"10.1097/GME.0000000000002496","url":null,"abstract":"<p><strong>Objective: </strong>Menopausal symptoms can significantly impact women's quality of life. Herbal interventions like Matricaria chamomilla (chamomile) have been suggested as potential remedies. However, their efficacy and safety remain underexplored.</p><p><strong>Methods: </strong>This triple-blind clinical trial enrolled 80 postmenopausal women meeting specific criteria. Inclusion criteria included participants in early or late perimenopause, defined by a symptom score >15, FSH levels >40, or 2 years since menopause, with no significant comorbidities. Participants were randomly assigned to intervention and placebo groups. In a triple-blind clinical trial with 80 postmenopausal women (aged 47-62) from Babol City Health Center, participants were randomly assigned to receive either chamomile (100 mg capsules with 1.2% apigenin, four times daily) or a placebo over 12 weeks. Symptoms of menopause were assessed using the Australian Menopause Association's Scorecard Symptom Questionnaire. Over 12 weeks, they received either chamomile or placebo capsules, with side effect assessments every 4 weeks.</p><p><strong>Results: </strong>Notable differences were found between the intervention and control groups in the overall scores on the symptom scorecard from baseline to 12 weeks' postintervention (-10.36; 95% confidence interval [CI], -13.84 to -6.92; P < 0.001). Specific subscores also improved in the intervention group: vasomotor (-2.25; 95% CI, -3.09 to -1.42; P < 0.001), psychological (-3.74; 95% CI, -5.29 to -2.20; P < 0.001), locomotor (-2.70; 95% CI, -3.63 to -1.77; P < 0.001), and urological (-1.89; 95% CI, -2.77 to -1.00; P < 0.001). Both groups showed significant changes in total symptom scores over time ( P < 0.001). Two participants experienced side effects, including mouth sores, skin spots, and itching, in the chamomile group, which led to their dropping out of the study.</p><p><strong>Conclusions: </strong>Chamomile intervention shows promise in alleviating menopausal symptoms, but its use warrants caution due to associated side effects. Further research is necessary to optimize dosage and mitigate adverse reactions for safer and more effective management of menopausal symptoms.</p>","PeriodicalId":18435,"journal":{"name":"Menopause: The Journal of The North American Menopause Society","volume":" ","pages":"353-358"},"PeriodicalIF":2.8,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143008066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Using machine learning models to identify severe subjective cognitive decline and related factors in nurses during the menopause transition: a pilot study.","authors":"Xiangyu Zhao, Xiaona Shen, Fengcai Jia, Xudong He, Di Zhao, Ping Li","doi":"10.1097/GME.0000000000002500","DOIUrl":"10.1097/GME.0000000000002500","url":null,"abstract":"<p><strong>Objective: </strong>This study aims to develop and validate a machine learning model for identifying individuals within the nursing population experiencing severe subjective cognitive decline (SCD) during the menopause transition, along with their associated factors.</p><p><strong>Methods: </strong>A secondary analysis was performed using cross-sectional data from 1,264 nurses undergoing the menopause transition. The data set was randomly split into training (75%) and validation sets (25%), with the Bortua algorithm employed for feature selection. Seven machine learning models were constructed and optimized. Model performance was assessed using area under the receiver operating characteristic curve, accuracy, sensitivity, specificity, and F1 score. Shapley Additive Explanations analysis was used to elucidate the weights and characteristics of various factors associated with severe SCD.</p><p><strong>Results: </strong>The average SCD score among nurses in the menopause transition was (5.38 ± 2.43). The Bortua algorithm identified 13 significant feature factors. Among the seven models, the support vector machine exhibited the best overall performance, achieving an area under the receiver operating characteristic curve of 0.846, accuracy of 0.789, sensitivity of 0.753, specificity of 0.802, and an F1 score of 0.658. The two variables most strongly associated with SCD were menopausal symptoms and the stage of menopause.</p><p><strong>Conclusions: </strong>The machine learning models effectively identify individuals with severe SCD and the related factors associated with severe SCD in nurses during the menopause transition. These findings offer valuable insights for the management of cognitive health in women undergoing the menopause transition.</p>","PeriodicalId":18435,"journal":{"name":"Menopause: The Journal of The North American Menopause Society","volume":" ","pages":"295-305"},"PeriodicalIF":2.8,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142979121","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Workplace physical activity, sitting time, and menopause symptoms.","authors":"Sophie E Carter, Alexander J Beaumont, Amy K Campbell","doi":"10.1097/GME.0000000000002497","DOIUrl":"10.1097/GME.0000000000002497","url":null,"abstract":"<p><strong>Objective: </strong>Increasing numbers of women are in employment during the menopause; however, menopause symptoms can negatively impact capacity to work. Aspects of the work environment, such as the amount of time spent in physical activity (PA) and sitting, may influence symptoms, yet this is unexplored. This study aimed to explore relationships between workplace PA and sitting, and menopause symptom severity.</p><p><strong>Methods: </strong>Using a cross-sectional study design, 264 perimenopausal or postmenopausal women were recruited to complete an online questionnaire assessing their self-reported workplace PA and sitting time, and their menopause symptom severity (menopause quality of life, hot flash interference, symptom severity). Multiple linear regression analyses examined the associations between menopause symptom severity and the time spent in PA (standing, walking, and physically demanding tasks) and sitting during work hours. Binomial logistical regression was used to assess if menopause symptom severity predicts whether women meet workplace activity guidelines.</p><p><strong>Results: </strong>No significant associations were observed between the time spent in PA or sitting while at work and menopause symptom severity ( P > 0.05). Menopause symptom severity did not significantly predict whether women met workplace activity guidelines ( P > 0.05).</p><p><strong>Conclusions: </strong>In a cohort of perimenopausal and postmenopausal women, self-reported time spent in PA and sitting while at work is not associated with menopause symptom severity. Further research is needed using device-based methods to assess PA and sitting time, to explore in more detail the influence of the time spent in these behaviors while at work on menopause symptoms.</p>","PeriodicalId":18435,"journal":{"name":"Menopause: The Journal of The North American Menopause Society","volume":" ","pages":"306-314"},"PeriodicalIF":2.8,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142951245","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Longitudinal changes in circulating cyclic guanosine monophosphate in women over the menopause transition compared to men: the Coronary Artery Risk Development in Young Adults (CARDIA) study.","authors":"Giuliana N Lee, Wendy Ying, Bharath Ambale-Venkatesh, Chike C Nwabuo, Henrique Doria de Vasconcellos, Erin D Michos, Pamela Ouyang, Chiadi Ndumele, Pamela J Schreiner, Jared P Reis, Donald M Lloyd-Jones, Cora E Lewis, Stephen Sidney, Colin O Wu, Ron Hoogeveen, Joao A C Lima, Wendy S Post, Dhananjay Vaidya","doi":"10.1097/GME.0000000000002526","DOIUrl":"https://doi.org/10.1097/GME.0000000000002526","url":null,"abstract":"<p><strong>Objective: </strong>The menopause transition is a period of accelerated cardiovascular disease (CVD) development in women, and sex differences in CVD incidence are reduced after menopause. Higher plasma cyclic guanosine monophosphate (cGMP) levels are also associated with greater CVD risk. Thus, we examined the changes in cGMP levels associated with the menopause transition.</p><p><strong>Methods: </strong>We measured plasma cGMP levels in 511 women and 283 men in the Coronary Artery Risk Development in Young Adults (CARDIA) study.</p><p><strong>Results: </strong>Over a 20-year follow-up period, women who completed the menopause transition had smaller reductions in cGMP relative to women who remained premenopausal (P < 0.05) but had similar changes compared to men (P = 0.3) after adjusting for demographic variables.</p><p><strong>Conclusions: </strong>Plasma cGMP changes through the menopause transition may reflect the underlying mechanisms associated with greater cardiovascular disease risk.</p>","PeriodicalId":18435,"journal":{"name":"Menopause: The Journal of The North American Menopause Society","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143710558","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Low creatinine to cystatin C ratio is associated with lower muscle volumes and poorer gait speeds in the longitudinal Integrated Women's Health Program cohort.","authors":"Darren Yuen Zhang Tan, Beverly Wen Xin Wong, Liang Shen, Ling-Jun Li, Eu-Leong Yong","doi":"10.1097/GME.0000000000002524","DOIUrl":"https://doi.org/10.1097/GME.0000000000002524","url":null,"abstract":"<p><strong>Objective: </strong>Little is known about the longitudinal associations between creatinine-cystatin C ratios (CCR) with muscle volume and function during the menopausal transition. We investigated the longitudinal relationship of baseline CCR, with muscle volumes measured by magnetic resonance imaging (MRI), and objectively measured muscle strength and physical performance after 6.6-year follow-up.</p><p><strong>Methods: </strong>Participants from the Integrated Women's Health Programme (IWHP) cohort (n = 891, baseline mean age 56.2 ± 6.0) who attended both baseline and follow-up visits underwent objectively measured muscle strength and physical performance assessments and MRI. Creatinine to cystatin C ratio was calculated as (creatinine [mg/dL] / cystatin C [mg/L]) and low CCR were those in the lowest tertile (CCR < 8.16). Multivariable regression analyses were used to determine the associations of baseline CCR with muscle volumes and function 6.6 years later.</p><p><strong>Results: </strong>Baseline low CCR was associated with lower MRI-measured muscle volumes and poorer physical function 6.6 years later. Compared to high CCR group, mean fat-free thigh muscle volume of the low CCR group was 0.350 L lower (95% CI, 0.183-0.518) after adjustment for covariates. Similarly, the low CCR group was associated with 0.029 m/s slower (95% CI, 0.006-0.053) slower mean usual gait and 0.049 m/s slower (95% CI, 0.020-0.078) mean narrow gait speeds. CCR was not associated with handgrip strength and repeated chair stands and one-leg stand tests.</p><p><strong>Conclusion: </strong>Low CCR at baseline was associated with lower fat-free muscle volumes and poorer gait speeds 6.6 years later. The potential of CCR as a predictive biomarker for adverse events related to sarcopenia in midlife women merits further investigation.</p>","PeriodicalId":18435,"journal":{"name":"Menopause: The Journal of The North American Menopause Society","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143657691","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Abnormal uterine bleeding is associated with fatigue during the menopause transition.","authors":"Siobán D Harlow, Ellen B Gold, Michelle M Hood, Alain A Mukwege, John F Randolph, Gail A Greendale","doi":"10.1097/GME.0000000000002525","DOIUrl":"https://doi.org/10.1097/GME.0000000000002525","url":null,"abstract":"<p><strong>Objective: </strong>During the menopause transition (MT), abnormal uterine bleeding, characterized by prolonged (PMB) or heavy (HMB) menstrual bleeding, occurs often. We assessed whether PMB or HMB was associated with fatigue.</p><p><strong>Methods: </strong>We used longitudinal daily menstrual calendar data from 2,329 participants in the Study of Women's Health Across the Nation to identify episodes of HMB and PMB. At seven annual follow-up visits, four symptoms of fatigue were queried (worn out, feeling tired, full of pep, having energy). General linear mixed models with random intercepts for each woman assessed the association between each fatigue variable and PMB or HMB recorded during the 6 months prior to each annual follow-up visit. Models were adjusted for race and ethnicity, age, body mass index, hormone therapy use, depressive and anxiety symptoms, perceived stress, sleep problems, cigarette use, and discrimination.</p><p><strong>Results: </strong>After adjustment, reporting three or more episodes of HMB in the prior 6 months was positively associated with feeling tired (odds ratio [OR] = 1.62, 95% CI = 1.11 to 2.38) and being worn out (OR = 1.44, 95% CI = 0.98 to 2.13), whereas three or more episodes of PMB in the prior 6-month window was negatively associated with being full of pep (OR = 0.68, 95% CI = 0.49 to 0.95).</p><p><strong>Conclusions: </strong>HMB and PMB during the MT were associated with increased odds of experiencing three symptoms of fatigue. Greater clinical attention to bleeding changes and associated symptoms, including fatigue and lack of energy, is warranted, as is education of women about potential health consequences of excessive menstrual bleeding during the MT.</p>","PeriodicalId":18435,"journal":{"name":"Menopause: The Journal of The North American Menopause Society","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143605589","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of postmenopausal bleeding.","authors":"Steven Goldstein","doi":"10.1097/GME.0000000000002522","DOIUrl":"https://doi.org/10.1097/GME.0000000000002522","url":null,"abstract":"","PeriodicalId":18435,"journal":{"name":"Menopause: The Journal of The North American Menopause Society","volume":"32 3","pages":"275-277"},"PeriodicalIF":2.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143502297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence of urinary tract infections in women with vulvovaginal atrophy and the impact of vaginal prasterone on the rate of urinary tract infections.","authors":"Rachel Rubin, May Sanaee, Alyssa Yee, Erick Moyneur, Katherine Dea, Alain Y Dury","doi":"10.1097/GME.0000000000002485","DOIUrl":"10.1097/GME.0000000000002485","url":null,"abstract":"<p><strong>Objective: </strong>The aims of this study were to assess the prevalence of urinary tract infections (UTI) in women newly diagnosed with vulvovaginal atrophy (VVA) versus women without VVA and to evaluate the potential of vaginal prasterone to be used in postmenopausal VVA women with UTI as prophylaxis to reduce the future UTI risk. As a first subgroup analysis, women using aromatase inhibitors, medications that stop the production of estrogen were analyzed. As a second subgroup analysis, we looked at women with diabetes to investigate whether the same prophylaxis approach should be considered.</p><p><strong>Methods: </strong>This observational retrospective inception cohort study was conducted using the Integrated Dataverse open-source claims database with data from February 2015 through January 2020.</p><p><strong>Results: </strong>A total of 22,245 women treated with prasterone for a minimum of 12 weeks were matched to women without any prescribed VVA-related treatment. Overall, women treated with prasterone have a significantly lower UTI prevalence compared to those untreated (6.58% vs 12.3%; P < 0.0001). The highest difference in UTI prevalence among the prasterone treated and untreated women was observed in those aged 65-74 (7.15% vs 16.2%; P < 0.0001). Among aromatase inhibitor users and women with diabetes, those treated with prasterone have a significantly lower UTI prevalence (4.90% vs 9.79%; P < 0.01 and 14.59% vs 20.48%; P < 0.0001, respectively).</p><p><strong>Conclusions: </strong>This study suggests that intravaginal prasterone may be a good candidate for prophylaxis in postmenopausal women with UTI to reduce future UTI risk, including for women taking aromatase inhibitors and women with diabetes. This study is based on real-world evidence and warrants further investigation in a clinical setting.</p>","PeriodicalId":18435,"journal":{"name":"Menopause: The Journal of The North American Menopause Society","volume":" ","pages":"217-227"},"PeriodicalIF":2.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12147743/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142951026","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A randomized controlled trial to evaluate a novel dual laser therapy for vulvar lichen sclerosus: exploratory study assessing the impact of menopausal status.","authors":"Irena Zivanovic, Marianne Gamper, Debra Fesslmeier, Helena Bischofberger, Volker Viereck","doi":"10.1097/GME.0000000000002478","DOIUrl":"10.1097/GME.0000000000002478","url":null,"abstract":"<p><strong>Objective: </strong>A randomized controlled trial showed that Neodymium:YAG/Erbium:YAG laser therapy was safe and significantly improved clinical outcomes and subjective symptoms of vulvar lichen sclerosus (LS). Most improvements were similar to those after the recommended first-line therapy with topical steroid. In this exploratory study, we wanted to analyze the impact of menopausal status on perception and treatment outcome.</p><p><strong>Methods: </strong>Sixty-six women with clinical lichen sclerosus were assigned to the laser or the steroid arm (2:1). Participants of the laser arm received four laser treatments with a follow-up of 6 months after treatment initiation. Clinical objective (LS score) and subjective outcomes (vulvovaginal symptoms questionnaire [VSQ], symptom visual analogue scale [VAS] score, patient satisfaction) were evaluated.</p><p><strong>Results: </strong>Nineteen of the 66 study participants were premenopausal, 47 postmenopausal. At baseline, premenopausal women were significantly younger (39.4 vs 67.4 yr, P < 0.001), only a few applied local estrogen (16% vs 74%, P < 0.001), and their VSQ score was higher (9.58 vs 7.32, P = 0.015) indicating more severe vulvovaginal symptoms. Laser therapy objectively led to similar clinical improvements for pre- and postmenopausal women (-2.62 vs -2.23, P = 0.437), but subjectively to a significantly higher improvement of the VSQ score in postmenopausal women (-4.13 vs -1.08, P = 0.005). Postmenopausal women were more satisfied with laser therapy than premenopausal women (71% vs 46%, P = 0.002).</p><p><strong>Conclusion: </strong>Compared to premenopausal women, postmenopausal women experienced a lower subjective burden of the disease and a better subjective improvement after laser therapy. Perceptions and expectations are age-dependent and should be considered when treating women with lichen sclerosus.</p>","PeriodicalId":18435,"journal":{"name":"Menopause: The Journal of The North American Menopause Society","volume":"32 3","pages":"228-233"},"PeriodicalIF":2.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12147725/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143502292","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fragmented QRS complexes in electrocardiogram and their relationship with somatic symptoms in postmenopausal women.","authors":"Busra Korpe, Caner Kose, Nazlı Turan Serifler, Vakkas Korkmaz, Huseyin Levent Keskin","doi":"10.1097/GME.0000000000002491","DOIUrl":"10.1097/GME.0000000000002491","url":null,"abstract":"<p><strong>Objective: </strong>Menopause significantly impacts cardiovascular health, yet the relationship between myocardial abnormalities and noncardiac symptoms in postmenopausal women remains underexplored. This study aims to investigate the association between fragmented QRS waves (fQRS) positivity on electrocardiograms (ECG) and somatic symptoms in postmenopausal women.</p><p><strong>Methods: </strong>We included 623 postmenopausal women attending a menopause clinic for routine annual gynecological examinations. Women were categorized into fQRS-positive (n = 248) and fQRS-negative (n = 375) groups based on ECG results analyzed by a blinded cardiologist. The Menopause Rating Scale (MRS) was used to assess menopausal symptoms across three subscales: somatic, psychological, and urogenital. Data on demographics, physical activity, and medical history were also collected. Statistical analyses included comparisons of MRS scores, and a binary logistic regression analysis was used to identify the relationship between fQRS positivity and somatic symptoms. Adjusted models were created for potential confounders.</p><p><strong>Results: </strong>Women with fQRS positivity reported significantly higher somatic symptoms and total MRS scores compared to those without fQRS positivity. Specifically, higher scores were observed in the fQRS-positive group for the somatic subscale and total MRS score. Binary logistic regression analysis revealed that fQRS positivity was significantly associated with somatic symptoms after adjusting for all confounders (odds ratio, 10.76; 95% CI, 7.21-16.07; P < 0.001).</p><p><strong>Conclusions: </strong>Postmenopausal women with fQRS positivity on ECG exhibit a higher severity of somatic symptoms compared to those without fQRS positivity. These findings suggest a potential link between somatic symptoms and myocardial conduction abnormalities indicated by fQRS positivity. Further research is needed to clarify the underlying mechanisms of this association.</p>","PeriodicalId":18435,"journal":{"name":"Menopause: The Journal of The North American Menopause Society","volume":" ","pages":"240-246"},"PeriodicalIF":2.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142950927","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}